tion medications are due to the availability of a variety of antipsychotics which are widely used for both acute schizophrenia and as maintenance medications. This cost estimate may help health care providers and policymakers better understand the economic burden of schizophrenia and identify services associated with the highest costs.

PMH30
INDIRECT COSTS (IC) OF ADULT WOMEN WITH ANXIETY DISORDERS (AD) IN THE UNITED STATES IN 2006 FROM THE MEDICAL EXPENDITURES PANEL SURVEY (MEPS)
Kerati A, Fappaport H
Department of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: To estimate the IC for adult women with AD in the United States in 2006. METHODS: Females > 17 years who reported AD were selected. A control group was created using propensity score matching. The components of indirect costs were annual national cost of missed work days for employed individuals, annual national cost of other bed days for unemployed individuals, and the present value of future productivity due to premature deaths. To calculate the number of missed work days attributable to AD, the unadjusted mean number of missed work days and other bed days for those without AD was multiplied by the regression coefficient for AD from the multivariate regression minus the unadjusted mean number of missed work days and other bed days for those without AD. Using the number days attributable to AD and the MEPS sample weights for each individual, the total cost of missed work days and other bed days attributable to AD in the United States was estimated. Mortality costs were calculated as the present value of future productivity due to premature deaths. The total amount of indirect costs was estimated by adding the total from morbidity estimate to the total from the mortality estimate. RESULTS: The hospital costs were $3,529, the morbidity costs were $14,215, and the mortality costs were $60.46 billion. CONCLUSIONS: Morbidity costs due to lost productivity were the major costs of IC and indicate a significant financial burden that can be reduced by disease management programs.

PMH31
TRAJECTORY ANALYSIS OF HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH HIGH DOSES OF DULOXETINE
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To examine healthcare cost patterns prior to and following duloxetine initiation in patients with major depressive disorder (MDD), focusing on patients whose dose was initially high or was titrated to high levels. METHODS: This was a retrospective analysis of 10,987 patients aged 18 to 64 years treated in a real-world clinical setting and enrolled in health insurance for the 6 months preceding and 12 months following initiation of duloxetine. Repeated measures and pre-post analyses were used to examine longitudinal healthcare cost trajectories before and after an initiation of low (<60 mg/day), standard (60 mg/day), and high (>60 mg/day) dose duloxetine. Classification and regression tree analysis was used to identify factors influencing patient heterogeneity in healthcare cost outcomes for patients whose doses were titrated to high levels. RESULTS: Low, standard, and high doses of duloxetine were initiated for 29.6%, 60.9%, and 9.5% of patients, respectively, with 13.7% receiving titrated high dose within 6 months duloxetine initiation. For those starting with a low dose, total costs increased in the months leading to and decreased in the months following initiation of treatment. Patients whose dose was initially >60 mg/day had higher costs both prior to and throughout the course of treatment as compared to patients treated with standard-dose duloxetine. Following dose escalation to >60 mg/day, costs were higher for medication but lower for inpatient services, resulting in total cost neutrality. Titration to high-dose therapy was cost beneficial for patients with histories of a mental disorder and high prior medical costs. CONCLUSIONS: Patients with MDD had costs increases leading to and cost declines following initiation of duloxetine therapy. Patients treated with <60 mg/day had higher healthcare costs both prior to and following initiation compared to those treated with ≤60 mg/day. Increases in pharmacy costs associated with escalation to high-dose therapy were offset by reduced inpatient costs.

PMH32
COMPARISON OF REAL-WORLD HEALTH CARE COSTS AFTER THE INITIATION OF SECOND-LINE DULOXETINE OR GENERIC SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
Swindle K1, Ivanova JF, Burnbaum HG2, Cummings AK3, Kantor E7, Schiller M, Clark T1, Reed C1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Analysis Group, Inc, New York, NY, USA, 3Analysis Group, Inc, Boston, MA, USA, 4Lilly UK, Withdean, Surrey, UK
OBJECTIVES: To compare real-world healthcare costs after initiation of second-line antidepressant treatment with duloxetine vs. generic selective serotonin reuptake inhibitors (SSRIs) for major depressive disorder (MDD). METHODS: Study sample was selected from a de-identified U.S. privately-insured claims database (2005-2009). Selection criteria: age 18-64 years, ≥1 MDD diagnosis (ICD-9-CM: 296.2, 296.3) in an inpatient setting or ≥2 MDD diagnoses in emergency room/outpatient settings, initiated on duloxetine therapy after a 3-month washout, initiation of a second-line treatment with duloxetine or generic SSRi (defined as the index date) no later than 90 days after the end of first-line treatment, continuous coverage eligibility from 6 months before the index date (baseline period) to 12 months after initiation of index date (post-index period). Using optimal matching on propensity scores and baseline costs, 838 patients initiating second-line duloxetine were matched to 838 patients initiating second-line generic SSRi. McNemar tests were used to compare proportions. Bias-corrected bootstrapping was used to compare healthcare costs (reimbursement to providers for medical services and prescription drugs) inflated to 2009 dollars. RESULTS: Before matching, second-line duloxetine compared with generic SSRi users were older, more likely to be female, had a higher rate of chronic pain, and had higher baseline prescription drug costs and $2,967 higher study period healthcare costs. After matching, there were no notable differences in baseline characteristics and total costs. Increased drug costs ($11,342 vs. $10,328, p = 2316) nor medical costs ($8,377 vs. $8,051 p = 0.7063) were significantly different between second-line duloxetine and generic SSRi users. Prescription drug costs were significantly higher for second-line duloxetine users ($2,777, p = 0.0001), largely due to differences in mental health-related drug costs ($1,605 $1,008, p = 0.001). CONCLUSIONS: Controlling for patient differences, this study found that second-line duloxetine users had similar medical costs and higher drug costs compared with second-line generic SSRi users.

PMH33
THE EFFECTIVENESS OF BUPRENOphINE-MEDICATION ASSISTED TREATMENT (B-MAT) IN AETNA'S OPIOID DEPENDENCE MEMBERS: AN ANALYSIS OF HEALTH CARE COSTS AND SERVICE UTILIZATION
Tkacz J1, Un H2, Leader Jr. D3, Ruestch C1,2
Health Analytics, LLC, Columbia, MD, 3Aetna Behavioral Health, Blue Bell, PA, USA
OBJECTIVES: Buprenorphine-mediated maintenance therapy (B-MAT) is an effective treatment for opioid dependence (OD), but may be considered cost-prohibitive by patients and health plans who manage its use based on ingredient cost alone. This analysis was conducted to estimate economic costs and benefits of B-MAT for OD from the perspective of a health plan sponsor. METHODS: A longitudinal, multivariate analysis was conducted using service use claims data among a sample of Aetna members with full benefit coverage and one or more diagnoses of OD during the 48 month measurement period (Q1 2006 to Q4 2009). OD members treated with B-MAT were matched to members treated with OD medications using nearest neighbor matching. Two six-month measurement periods were constructed around the index date: a six-month pre-period and a six-month post-period. RESULTS: During the six-month post-period, B-MAT members filled an average of 29 (P = 0.001) more prescriptions and had a use average of 0.21 more psychiatrist visits (P = 0.001) than non-B-MAT members, but utilized significantly fewer behavioral health inpatient hospital admissions (−0.82), behavioral health hospital days (−0.71), medical inpatient hospital days (−0.39), and emergency room visits (−0.31, P = 0.001). Concerning healthcare costs, B-MAT members spent $5305 less on inpatient hospital costs (P = 0.002), $542 less on emergency room costs (P = 0.016), and $6,378 less on total healthcare costs per member compared to non-B-MAT members (P = 0.001). CONCLUSIONS: Though B-MAT patients incur higher pharmacy costs, they use fewer expensive healthcare services in other areas, resulting in an overall positive cost-benefit. Assuming present results remain in direction and magnitude across other health plans, and from year to year, health plans can experience considerable savings using B-MAT as a first line of treatment for OD supported by outpatient services such as office based providers and counselors.

PMH34
MEASURING THE IMPACT OF PERSISTENCE WITH PSYCHOTROPIC DRUG THERAPY ON TREATMENT COSTS FOR PATIENTS WITH SCHIZOPHRENIA
Zolfaghari S, McCombs JL
OCS School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: To investigate the relationship between persistence with drug therapy and treatment costs in patients with schizophrenia. METHODS: Paid claims data from a commercial insurer was used to identify patients with schizophrenia. The unit of observation was the drug treatment episode. A total of 21,570 episodes were included in the analysis (2006-2009). Persistence was defined as not having a treatment gap of 60 days or more. RESULTS: Mean study period treatment costs ($11,342 vs. $10,328, P = 0.2316) nor medical costs ($8,377 vs. $8,051, P = 0.7063) were significantly different between second-line duloxetine and generic SSRi users. Prescription drug costs were significantly higher for second-line duloxetine users ($2,777, P = 0.0001), largely due to differences in mental health-related drug costs ($1,605 vs. $1,008, P = 0.001). CONCLUSIONS: Controlling for patient differences, this study found that second-line duloxetine users had similar medical costs and higher drug costs compared with second-line generic SSRi users.

PMH35
COMPARISONS OF MENTAL HEALTH-RELATED MEDICAL CARE UTILIZATION AND COSTS FOLLOWING THE INITIATION OF ORAL VersUS LONG-ActING INJECTABLE RISPERIDONE IN PATIENTS WITH SCHIZOPHRENIA
PACIN, Kim DN, Rascati KL
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To assess the patterns of mental-health related medical care utilization in patients with schizophrenia initiating on either oral or